COGENT BIOSCIENCES INC (COGT)

US19240Q2012 - Common Stock

6.72  +0.2 (+3.07%)

After market: 6.72 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to COGT. COGT was compared to 592 industry peers in the Biotechnology industry. COGT has a great financial health rating, but its profitability evaluates not so good. COGT is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

COGT had negative earnings in the past year.
In the past year COGT has reported a negative cash flow from operations.
COGT had negative earnings in each of the past 5 years.
In the past 5 years COGT always reported negative operating cash flow.

1.2 Ratios

COGT's Return On Assets of -61.39% is on the low side compared to the rest of the industry. COGT is outperformed by 61.22% of its industry peers.
COGT has a Return On Equity (-74.64%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -61.39%
ROE -74.64%
ROIC N/A
ROA(3y)-46.38%
ROA(5y)-55%
ROE(3y)-54.41%
ROE(5y)-67.93%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

COGT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, COGT has more shares outstanding
COGT has more shares outstanding than it did 5 years ago.
COGT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

COGT has an Altman-Z score of 3.31. This indicates that COGT is financially healthy and has little risk of bankruptcy at the moment.
COGT's Altman-Z score of 3.31 is fine compared to the rest of the industry. COGT outperforms 72.96% of its industry peers.
COGT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.31
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 7.09 indicates that COGT has no problem at all paying its short term obligations.
COGT's Current ratio of 7.09 is fine compared to the rest of the industry. COGT outperforms 66.33% of its industry peers.
COGT has a Quick Ratio of 7.09. This indicates that COGT is financially healthy and has no problem in meeting its short term obligations.
COGT has a better Quick ratio (7.09) than 66.33% of its industry peers.
Industry RankSector Rank
Current Ratio 7.09
Quick Ratio 7.09

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.04% over the past year.
EPS 1Y (TTM)2.04%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 21.25% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.72%
EPS Next 2Y6.91%
EPS Next 3Y11.29%
EPS Next 5Y21.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

COGT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year COGT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.91%
EPS Next 3Y11.29%

0

5. Dividend

5.1 Amount

No dividends for COGT!.
Industry RankSector Rank
Dividend Yield N/A

COGENT BIOSCIENCES INC

NASDAQ:COGT (3/28/2024, 7:04:54 PM)

After market: 6.72 0 (0%)

6.72

+0.2 (+3.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap698.28M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.39%
ROE -74.64%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 7.09
Quick Ratio 7.09
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)2.04%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y13.72%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y